PATHFINDER: Evaluating the Optimal First-Line Treatment Strategy for Moderate-to-Severely Active Ileal-dominant Crohn's Disease
NCT05928039
Recruiting
There are currently three classes of biologic treatments approved in Canada for the management of moderate-to-severe Crohn's disease: anti-tumor necrosis factor \[TNF\] alpha, anti-integrin, and anti-interleukin \[IL\]-23 targeted agents. The purpose of this trial is to determine which of these three classes of biologics results in the highest percentage of patients with small bowel (ileal) Crohn's disease entering into endoscopic remission without needing corticosteroids at 1 year. Endoscopic r... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/06/2025
Locations: University of Calgary, Calgary, Alberta +19 locations
Conditions: Crohn Disease
Register for Updates
FIRE-Diet: Food as an Intervention to Reduce the Effects of Woodsmoke Exposure on Respiratory Health
NCT06711614
Recruiting
Research suggests that consuming more fatty fish, fruits, and vegetables could potentially shield the lungs from the negative impacts of air pollution. The research team will look at whether a dietary intervention aimed at increasing intake of these foods can protect the lungs from woodsmoke as the air pollutant and look into how this works.
Gender:
ALL
Ages:
Between 19 years and 40 years
Trial Updated:
06/06/2025
Locations: University of British Columbia, Vancouver, British Columbia
Conditions: Healthy Individuals
Register for Updates
Targeted Pediatric High-Grade Glioma Therapy
NCT05839379
Recruiting
The goal of this study is to perform genetic sequencing on brain tumors from children, adolescents, and young adult patients who have been newly diagnosed with a high-grade glioma. This molecular profiling will decide if patients are eligible to participate in a subsequent treatment-based clinical trial based on the genetic alterations identified in their tumor.
Gender:
ALL
Ages:
Between 12 months and 39 years
Trial Updated:
06/06/2025
Locations: Children's Hospital Colorado, Aurora, Colorado +17 locations
Conditions: High Grade Glioma, Diffuse Intrinsic Pontine Glioma, Anaplastic Astrocytoma, Glioblastoma, Glioblastoma Multiforme, Diffuse Midline Glioma, H3 K27M-Mutant, Metastatic Brain Tumor, WHO Grade III Glioma, WHO Grade IV Glioma
Register for Updates
M3-JIA: Making Mindfulness Matter for Children With JIA
NCT06376149
Recruiting
The investigator will evaluate the efficacy of M3©, an intervention for patients with JIA and their caregivers. Children with Juvenile arthritis and their parents will attend an 8 week online program called Making Mindfulness Matter (M3). This is a facilitator-led program that integrates knowledge and skills related to mindfulness, social-emotional learning, neuroscience, and positive psychology to promote coping and resiliency for children and families in context of the challenges of pediatric... Read More
Gender:
ALL
Ages:
Between 4 years and 12 years
Trial Updated:
06/06/2025
Locations: McMaster Children's Hospital,, Hamilton, Ontario +2 locations
Conditions: Juvenile Idiopathic Arthritis, Children, Mental Health, Mental Well-being
Register for Updates
Neoadjuvant Chemotherapy, Excision And Observation vs Chemoradiotherapy For Rectal Cancer
NCT06205485
Recruiting
This study is being done to answer the following questions: Is the chance of rectal cancer responding the same if chemotherapy alone is given before limited surgery compared to chemotherapy and radiation therapy given together before limited surgery? If radiation therapy is not given, is quality of life better?
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/05/2025
Locations: Cancer Center at Saint Joseph's, Phoenix, Arizona +67 locations
Conditions: Rectal Cancer
Register for Updates
HCRN Endoscopic Versus Shunt Treatment of Hydrocephalus in Infants
NCT04177914
Recruiting
Hydrocephalus is a potentially debilitating neurological condition that primarily affects babies under a year of age and has traditionally been treated by inserting a shunt between the brain and the abdomen. A newer endoscopic procedure offers hope of shunt- free treatment that may reduce complications over a child's life, but it is not clear if the endoscopic procedure results in similar intellectual outcome as shunt. Therefore, the investigators propose a randomized trial to compare intellectu... Read More
Gender:
ALL
Ages:
Between 1 day and 104 weeks
Trial Updated:
06/05/2025
Locations: Children's of Alabama, Birmingham, Alabama +20 locations
Conditions: Hydrocephalus
Register for Updates
Recombinant Factor VIIa (rFVIIa) for Hemorrhagic Stroke Trial
NCT03496883
Recruiting
The objective of the rFVIIa for Acute Hemorrhagic Stroke Administered at Earliest Time (FASTEST) Trial is to establish the first treatment for acute spontaneous intracerebral hemorrhage (ICH) within a time window and subgroup of patients that is most likely to benefit. The central hypothesis is that rFVIIa, administered within 120 minutes from stroke onset with an identified subgroup of patients most likely to benefit, will improve outcomes at 180 days as measured by the Modified Rankin Score (m... Read More
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
06/05/2025
Locations: University of Alabama Hospital, Birmingham, Alabama +87 locations
Conditions: Intracerebral Hemorrhage
Register for Updates
Bone and Muscle Health Following Sleeve Gastrectomy in Men, Premenopausal and Postmenopausal Women
NCT06547515
Recruiting
Background: Bariatric surgery is gaining in popularity. While it's health benefits are undisputed, the older malabsorptive bariatric procedures (Roux-in-Y gastric bypass - RYGB and biliopancreatic diversion - BPD) are associated with an increased risk of fractures and falls as early as 3-5 years after surgery. Sleeve gastrectomy - SG is now the most performed bariatric procedure. Although SG does not cause malabsorption, it is predicted to result in bone and muscle loss via weight loss and weigh... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/05/2025
Locations: Centre de recherche de l'IUCPQ, Québec, Not set
Conditions: Bariatric Surgery, Bone Health, Severe Obesity, Muscle Health
Register for Updates
90Yttrium Colloid for the Treatment of Cystic Sellar/Parasellar Tumors
NCT02081768
Recruiting
There is no consensus in the literature on the best way to treat cystic lesions of the pituitary area. Patients who are symptomatic from these tumours are rare. The cystic form of tumours present special challenges since traditional treatment modalities (surgery and/or external radiation) are often not able to completely remove or treat the cyst wall without major morbidity or even mortality. There is no 'best practice' for the treatment of cystic tumours per se. Treatments available to patient... Read More
Gender:
ALL
Ages:
17 years and above
Trial Updated:
06/05/2025
Locations: Halifax Infirmary, Halifax, Nova Scotia
Conditions: Cystic Tumors of the Sellar/Parasellar Region
Register for Updates
UBC Breakfast Study 2.0
NCT06814171
Recruiting
Type 2 diabetes (T2D), a prevalent metabolic disorder impacting \>3 million Canadians, is characterized by insulin resistance and high blood glucose. Chronically elevated blood glucose (i.e., hyperglycemia) and swings in glucose (i.e., glucose variability) contribute to complications of T2D. Specifically, post-meal hyperglycemic spikes are independent risk factors for cardiovascular disease and mortality. People with T2D often exhibit a different circadian pattern from healthy individuals, with... Read More
Gender:
ALL
Ages:
Between 30 years and 79 years
Trial Updated:
06/05/2025
Locations: University of British Columbia - Okanagan, Kelowna, British Columbia
Conditions: Type 2 Diabetes
Register for Updates
Safety and Efficacy of TSHA-102 in Adolescent and Adult Females With Rett Syndrome (REVEAL Adult Study)
NCT05606614
Recruiting
The REVEAL Adult Study is a multi-center, Phase 1/2 open-label, dose-escalation study of TSHA-102, an investigational gene therapy, in adult females with Rett syndrome. The safety, tolerability, and preliminary efficacy of two dose levels will be evaluated. The study duration is estimated to be up to 63 months.
Gender:
FEMALE
Ages:
12 years and above
Trial Updated:
06/05/2025
Locations: UC San Diego, La Jolla, California +5 locations
Conditions: Rett Syndrome
Register for Updates
Feasibility of a Diet Intervention for Juvenile Arthritis
NCT06474546
Recruiting
Families of children with arthritis are highly interested in the benefits of diet to improve their child's disease and future health outcomes. Previous research shows that the germs - bacteria and other organisms - that live in the intestines (gut microbiome) are important to how well immune systems work, and that what people eat changes their gut microbiome. The investigators want to study whether a certain diet - based on the principles of the Mediterranean Diet - will improve arthritis for ch... Read More
Gender:
ALL
Ages:
Between 8 years and 18 years
Trial Updated:
06/05/2025
Locations: University of Manitoba, Winnipeg, Manitoba +6 locations
Conditions: Arthritis, Juvenile, Arthritis, Childhood, Juvenile Idiopathic Arthritis
Register for Updates